Dr Lal Pathlabs
- All
- News
- Videos
-
Will Stocks Like IEX, IRCTC, And Dr Lal Pathlabs Ever Recover?
What's ailing stocks like IEX, IRCTC, and Dr Lal Pathlabs?
-
Delhi Diagnostics Lab Sounds Caution Over Covid Testing Material Shortage
A large diagnostic chain has sounded caution over an impending shortage of material used in testing for COVID-19 amid a surge in cases across the country in what is now being called a deadly second wave.
-
Dr Lal Pathlabs Left Millions of Patients’ Sensitive Data on Public Server: Report
Australia-based security expert Sami Toivonen first discovered this sensitive data last month, and he immediately reported this lapse of security to Dr Lal PathLabs. While the company took the necessary measures to shut down access to the storage bucket, it did not respond to Toivonen. The spreadsheets contained sensitive information like patient n...
-
L&T Infotech's Rs 1,200 Crore IPO Fails To Excite Analysts: 10 Things To Know
Investors in the primary market have reasons to cheer, with many of the recent initial public offers (IPOs) returning huge listing gains. Blockbuster listings of Dr Lal PathLabs, Alkem Labs, TeamLease Services, Thyrocare Tech and more recently Mahanagar Gas, have boosted the confidence of retail investors in IPOs.
-
Nectar Lifesciences, Just Dial, IRCTC in Fortune India's 'Next 500' List
Just Dial, UTI Asset Management Company and IRCTC are among the firms that have made it to the Fortune Next 500 list of Indian companies, which has been topped by Dynamatic Technologies
-
Dr Lal PathLabs, Emami, Havells Among Citi's Top Midcap Bets
Citi's top midcap picks are Apollo Hospital, Container Corp, Dish TV, Dr Lal PathLabs, Emami, Exide, Federal Bank, GSPL, Havells India and Petronet.
-
Thyrocare Technologies Soars 49% In Blockbuster Listing
Last year, Dr Lal PathLabs, which is the bigger rival of Thyrocare had witnessed similar response to its IPO, by rising over 50 per cent on the date of debut.
-
Missed Dr Lal PathLabs IPO? Thyrocare Technologies May Be A Good Option
Thyrocare Technologies is the second diagnostic service provider in India after Dr Lal Pathlabs to come out with an IPO. Investors can buy a minimum of 33 shares. The IPO will close on April 29.
-
Thyrocare Technologies IPO To Open On April 27
Diagnostics company Thyrocare Technologies will hit the capital markets on April 27 to raise funds through an initial public offering.
-
New Entrants Stay Afloat as Dalal Street Sinks Deep
A number of new entrants to the stock market this fiscal year have managed to stay above their IPO levels, even as some big names like Coffee Day Enterprises and InterGlobe Aviation have fallen sharply from their peaks.
-
Dr Lal PathLabs Q3 Profit More Than Doubles to Rs 61 Crore
Diagnostic services provider Dr Lal PathLabs on Saturday reported over two-fold jump in consolidated net profit at Rs 60.82 crore for the third quarter ended December 31, 2015.
-
IPO Drought Ends as Companies Raise Rs 13,600 Crore in 2015
Ending the IPO drought, 21 companies have entered Dalal Street in 2015 with initial public offers to garner Rs 13,600 crore - the highest in five years - and an impressive pipeline is already in place for the new year.
-
Buy Sun Pharma, Avoid Dr Lal PathLabs, Says Mayuresh Joshi
Mayuresh Joshi of Angel Broking says prices of some midcap stocks have run-up ahead of earnings expectations. Investors should buy banks, auto and select pharma names, while avoiding capital goods stocks, he added.
-
Sensex Ends 260 Points Higher; Dr Lal PathLabs Soars Over 50% on Debut
Sensex and Nifty hit their highest level in nearly three weeks on Wednesday in the absence of foreign selling pressure ahead of year-end holidays, and following overnight gains on Wall Street after data showed the US economy grew at a healthy clip in the third quarter.
-
Dr Lal PathLabs to Enter New Geographies, Says CEO
Dr Lal PathLabs showcased a stellar listing on the stock exchanges today. Shares of Dr Lal PathLabs rallied as much as 42 per cent to hit high of Rs 783.45 on the National Stock Exchange against its issue price of Rs 550.
-
Will Stocks Like IEX, IRCTC, And Dr Lal Pathlabs Ever Recover?
What's ailing stocks like IEX, IRCTC, and Dr Lal Pathlabs?
-
Delhi Diagnostics Lab Sounds Caution Over Covid Testing Material Shortage
A large diagnostic chain has sounded caution over an impending shortage of material used in testing for COVID-19 amid a surge in cases across the country in what is now being called a deadly second wave.
-
Dr Lal Pathlabs Left Millions of Patients’ Sensitive Data on Public Server: Report
Australia-based security expert Sami Toivonen first discovered this sensitive data last month, and he immediately reported this lapse of security to Dr Lal PathLabs. While the company took the necessary measures to shut down access to the storage bucket, it did not respond to Toivonen. The spreadsheets contained sensitive information like patient n...
-
L&T Infotech's Rs 1,200 Crore IPO Fails To Excite Analysts: 10 Things To Know
Investors in the primary market have reasons to cheer, with many of the recent initial public offers (IPOs) returning huge listing gains. Blockbuster listings of Dr Lal PathLabs, Alkem Labs, TeamLease Services, Thyrocare Tech and more recently Mahanagar Gas, have boosted the confidence of retail investors in IPOs.
-
Nectar Lifesciences, Just Dial, IRCTC in Fortune India's 'Next 500' List
Just Dial, UTI Asset Management Company and IRCTC are among the firms that have made it to the Fortune Next 500 list of Indian companies, which has been topped by Dynamatic Technologies
-
Dr Lal PathLabs, Emami, Havells Among Citi's Top Midcap Bets
Citi's top midcap picks are Apollo Hospital, Container Corp, Dish TV, Dr Lal PathLabs, Emami, Exide, Federal Bank, GSPL, Havells India and Petronet.
-
Thyrocare Technologies Soars 49% In Blockbuster Listing
Last year, Dr Lal PathLabs, which is the bigger rival of Thyrocare had witnessed similar response to its IPO, by rising over 50 per cent on the date of debut.
-
Missed Dr Lal PathLabs IPO? Thyrocare Technologies May Be A Good Option
Thyrocare Technologies is the second diagnostic service provider in India after Dr Lal Pathlabs to come out with an IPO. Investors can buy a minimum of 33 shares. The IPO will close on April 29.
-
Thyrocare Technologies IPO To Open On April 27
Diagnostics company Thyrocare Technologies will hit the capital markets on April 27 to raise funds through an initial public offering.
-
New Entrants Stay Afloat as Dalal Street Sinks Deep
A number of new entrants to the stock market this fiscal year have managed to stay above their IPO levels, even as some big names like Coffee Day Enterprises and InterGlobe Aviation have fallen sharply from their peaks.
-
Dr Lal PathLabs Q3 Profit More Than Doubles to Rs 61 Crore
Diagnostic services provider Dr Lal PathLabs on Saturday reported over two-fold jump in consolidated net profit at Rs 60.82 crore for the third quarter ended December 31, 2015.
-
IPO Drought Ends as Companies Raise Rs 13,600 Crore in 2015
Ending the IPO drought, 21 companies have entered Dalal Street in 2015 with initial public offers to garner Rs 13,600 crore - the highest in five years - and an impressive pipeline is already in place for the new year.
-
Buy Sun Pharma, Avoid Dr Lal PathLabs, Says Mayuresh Joshi
Mayuresh Joshi of Angel Broking says prices of some midcap stocks have run-up ahead of earnings expectations. Investors should buy banks, auto and select pharma names, while avoiding capital goods stocks, he added.
-
Sensex Ends 260 Points Higher; Dr Lal PathLabs Soars Over 50% on Debut
Sensex and Nifty hit their highest level in nearly three weeks on Wednesday in the absence of foreign selling pressure ahead of year-end holidays, and following overnight gains on Wall Street after data showed the US economy grew at a healthy clip in the third quarter.
-
Dr Lal PathLabs to Enter New Geographies, Says CEO
Dr Lal PathLabs showcased a stellar listing on the stock exchanges today. Shares of Dr Lal PathLabs rallied as much as 42 per cent to hit high of Rs 783.45 on the National Stock Exchange against its issue price of Rs 550.
